The AAV vector toolkit: poised at the clinical crossroads.

Published

Journal Article (Review)

The discovery of naturally occurring adeno-associated virus (AAV) isolates in different animal species and the generation of engineered AAV strains using molecular genetics tools have yielded a versatile AAV vector toolkit. Promising results in preclinical animal models of human disease spurred the much awaited transition toward clinical application, and early successes in phase I/II clinical trials for a broad spectrum of genetic diseases have recently been reported. As the gene therapy community forges ahead with cautious optimism, both preclinical and clinical studies using first generation AAV vectors have highlighted potential challenges. These include cross-species variation in vector tissue tropism and gene transfer efficiency, pre-existing humoral immunity to AAV capsids and vector dose-dependent toxicity in patients. A battery of second generation AAV vectors, engineered through rational and combinatorial approaches to address the aforementioned concerns, are now available. This review will provide an overview of preclinical studies with the ever-expanding AAV vector portfolio in large animal models and an update on new lead AAV vector candidates poised for clinical translation.

Full Text

Duke Authors

Cited Authors

  • Asokan, A; Schaffer, DV; Samulski, RJ

Published Date

  • April 2012

Published In

Volume / Issue

  • 20 / 4

Start / End Page

  • 699 - 708

PubMed ID

  • 22273577

Pubmed Central ID

  • 22273577

Electronic International Standard Serial Number (EISSN)

  • 1525-0024

Digital Object Identifier (DOI)

  • 10.1038/mt.2011.287

Language

  • eng

Conference Location

  • United States